Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer.

Address correspondence to Rona Yaeger, MD, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, 10th Floor, New York, NY 10065. Tel 646-888-5109. Fax 646-888-4254. yaegerr@mskcc.org. *These authors contributed equally. Author contributions Study concept and design: S.M., H.W., N.S., R.Y. Acquisition of data: S.M., R.Y. Analysis and interpretation of data: S.M., H.W., S.N., W.K.C., N.S., R.Y. Drafting of manuscript: S.M., H.W., N.S., R.Y. Critical revision of manuscript: all authors

[1]  Jeffrey W. Clark,et al.  Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. , 2019, The oncologist.

[2]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[3]  J. Marshall,et al.  A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer , 2018, Cancer.

[4]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[5]  Ahmet Zehir,et al.  Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. , 2017, JCO precision oncology.

[6]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[7]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[8]  D. Busam,et al.  Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis , 2012, Oncogene.

[9]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[10]  R. Fodde,et al.  The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. , 2002, Human molecular genetics.